Cholestatic and Autoimmune Liver Diseases SIG: Bile Acid Signaling and Cholestatic Liver Diseases

Product not yet rated

Recorded On: 11/08/2019

Recent approval of the synthetic FXR agonist obeticholic acid for primary biliary cholangitis treatment shows that targeting nuclear receptors in treating liver diseases, particularly cholestatic and autoimmune conditions, has therapeutic potential.

Saul J. Karpen
Keith D. Lindor
Huiping Zhou

Key:

Complete
Failed
Available
Locked
Overview of Bile Acid Receptors
Open to view video.
Open to view video. Presenter: Huiping Zhou
Bile Acid Signaling in Genetic Cholestatic Syndromes
Open to view video.
Open to view video. Presenter: Saul J. Karpen
Ursodiol: 20 Years of Experience: Where Do We Stand?
Open to view video.
Open to view video. Presenter: Keith D. Lindor
Final Evaluation
Final Evaluation
7 Questions
7 Questions Please complete the following evaluation form to share your feedback on this activity.